## Filings that contain financial statements UnitedHealth Group furnishes condensed consolidated financial statements (statements of operations, balance sheets, statements of cash flows, plus supplemental financial information) in the Exhibit 99.1 earnings press releases attached to its Item 2.02 Forms 8-K: - Form 8-K filed July 16, 2026, accession 0000731766-26-000191: second quarter 2026 (three and six months ended June 30, 2026). - Form 8-K filed April 21, 2026, accession 0000731766-26-000121: first quarter 2026 (three months ended March 31, 2026). - Form 8-K filed January 27, 2026, accession 0000731766-26-000025: fourth quarter and full year 2025. - Form 8-K filed October 28, 2025, accession 0000731766-25-000301: third quarter 2025 (three and nine months ended September 30, 2025). ## Earnings releases and guidance - **July 16, 2026 (second quarter 2026; 0000731766-26-000191).** Revenues were $112.0 billion and earnings from operations were $8.0 billion. GAAP earnings were $6.04 per share and adjusted earnings were $6.38 per share. The medical care ratio was 86.7% (89.4% a year earlier), including $860 million of net favorable prior period development; the operating cost ratio was 12.7% (12.3%). Cash flows from operations were $11.1 billion, and the debt-to-capital ratio was 41.2%. UnitedHealthcare served 48.5 million people, down 525,000 sequentially. The company raised its 2026 outlook: adjusted earnings of $19.50 to $20.00 per share (from greater than $17.75 set January 27, 2026), GAAP earnings of $18.45 to $18.95 per share (from greater than $17.10), earnings from operations greater than $25,450 million (from greater than $24,000 million), a medical care ratio of 88.1% plus or minus 25 basis points (from 88.8% plus or minus 50), cash flows from operations of about $24.0 billion (from greater than $18.0 billion), and share repurchases of at least $5.0 billion (from about $2.5 billion). The company repurchased $4.0 billion of stock through mid-July 2026. - **April 21, 2026 (first quarter 2026; 0000731766-26-000121).** Revenues were $111.7 billion, GAAP earnings were $6.90 per share and adjusted earnings were $7.23 per share. The medical care ratio was 83.9% and the operating cost ratio was 13.8%. Full year 2026 outlook was raised to GAAP earnings of greater than $17.35 per share and adjusted earnings of greater than $18.25 per share. - **January 27, 2026 (fourth quarter and full year 2025; 0000731766-26-000025).** Full year 2025 revenues were $447.6 billion, GAAP earnings were $13.23 per share and adjusted earnings were $16.35 per share. A fourth quarter charge of $1.6 billion net of taxes ($1.78 per share) covered final cyberattack costs, net portfolio divestitures and restructuring, and was excluded from adjusted earnings. Initial 2026 outlook: revenues greater than $439.0 billion, earnings from operations greater than $24.0 billion, GAAP earnings greater than $17.10 per share and adjusted earnings greater than $17.75 per share. - **October 28, 2025 (third quarter 2025; 0000731766-25-000301).** Revenues were $113.2 billion; GAAP earnings were $2.59 per share and adjusted earnings were $2.92 per share; the medical care ratio was 89.9%. The 2025 outlook was raised to GAAP earnings of at least $14.90 per share and adjusted earnings of at least $16.25 per share. The release states the Amedisys transaction closed on August 14, 2025. - **January 12, 2026 (0000731766-26-000020).** Item 7.01: management intended to reaffirm, in investor meetings, the adjusted 2025 earnings per share expectations disclosed on October 28, 2025. - **September 9, 2025, Form 8-K/A (0000731766-25-000247).** Item 7.01: management intended to reaffirm adjusted 2025 earnings per share expectations from July 29, 2025, which incorporated closing the Amedisys acquisition in August 2025 (expected to be dilutive to adjusted earnings per share), and estimated about 78% of Medicare Advantage membership in plans rated 4 stars or higher for Star Year 2026, based on preliminary CMS data. ## M&A and portfolio changes - **Alegeus Technologies: signed in the first quarter of 2026, closed July 2, 2026.** The April 21, 2026 release (0000731766-26-000121) states the company entered into an agreement to acquire Alegeus, a consumer-directed healthcare account platform, subject to regulatory review and expected to be earnings neutral to 2026. The July 16, 2026 release (0000731766-26-000191) states Optum Insight "completed its acquisition of Alegeus on July 2, 2026." The press releases give no purchase price. - **Optum UK sale: completed.** The April 21, 2026 release states the company completed the sale of the Optum UK business, with $400 million in net proceeds committed to the United Health Foundation, and describes the company as refocused on U.S. health care and exiting non-U.S. businesses. - **Amedisys: closed August 14, 2025** (October 28, 2025 release, 0000731766-25-000301). ## Capital actions - April 21, 2026 release: the company entered into an arrangement to buy back at least $2 billion of its common stock, expected to be completed by the end of the second quarter 2026. The July 16, 2026 release raises the full year 2026 repurchase outlook to at least $5.0 billion. ## Management and board - **February 25, 2026 (0000731766-26-000046), Item 5.02.** On February 23, 2026 the Compensation and Human Resources Committee amended Stephen Hemsley's May 14, 2025 stock option to add a two-year holding requirement after the three-year cliff vesting; net shares from exercise must be held until May 14, 2030, except death or disability. - **March 2, 2026 (0000731766-26-000064), Item 5.02.** Dennis Stankiewicz, Corporate Controller, was appointed Chief Accounting Officer effective March 2, 2026. Tom Roos, Chief Accounting Officer since August 2015, became Chief Financial Officer of Optum Insight. - **November 21, 2025 (0000731766-25-000314), Item 5.02.** Scott Gottlieb, M.D., was appointed an independent director, announced November 18, 2025. - **June 5, 2026 (0000731766-26-000138), Item 5.07.** At the June 1, 2026 annual meeting, all nine directors were elected, say-on-pay was approved (82.74% of votes for), Deloitte & Touche LLP was ratified as auditor for 2026, and a shareholder proposal for an independent board chair was not approved (20.24% for). - **November 13, 2025 (0000731766-25-000310), Item 5.03.** Bylaws were amended, effective November 6, 2025, solely to reflect a change in the Delaware registered office and registered agent. ## Routine investor-conference filings Item 7.01 notices of conference appearances: UBS Global Healthcare Conference, November 10, 2025 (0000731766-25-000308); Barclays Global Healthcare Conference, March 10, 2026 (0000731766-26-000067); Bank of America Securities Health Care Conference, May 12, 2026 (0000731766-26-000129); Wells Fargo Healthcare Conference, September 9, 2026 (0000731766-26-000205). These carry no new financial information.